Loading...
Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ
Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly characterized. Thus, there is an unmet clinical need fo...
Na minha lista:
| Udgivet i: | Front Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7380268/ https://ncbi.nlm.nih.gov/pubmed/32765529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01527 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|